De-León-Mazariegos Romulo, Canedo-Patzi Marcela, Pérez-Enríquez Bernardo, Candanedo-Gonzalez Fernando, Saqui-Salces Milena, Gamboa-Domínguez Armando, Rull-Rodrigo Juan A
Clínica de Tiroides, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Tlalpan, México, DF.
Rev Invest Clin. 2004 Sep-Oct;56(5):623-8.
Galectin-3 is considered useful in identifying lesions included in the term follicular tumour.
To evaluate galectin-3's power to discriminate among diverse thyroid lesions and to identify a set point of expression at which there is the least possible false positive results.
26 follicular carcinomas and 104 assorted thyroid lesions were analysed (8 Hashimoto's thyroiditis, 18 goiter, 44 adenoma, 27 papillary carcinoma and 7 normal glands). Immunohistochemistry for galectin-3 was performed way (NCL-GAL-3, 1:100, Novocastra, UK). In a blinded manner intensity and percentage of expression were evaluated, as was its capacity to identify the previously mentioned thyroid entities with 2 x 2 tables. Minimum reactivity set point values were identified and the one which presented the least false positive cases was selected.
A reaction was considered positive when 25% of the cells were marked, in which case neither the Hashimoto's thyroiditis, goiter, nor the residual tissue were positive for galectin-3. A positive galectin-3 reaction was identified in 4/44 adenomas, 5/26 follicular carcinomas and 18/27 papillary carcinomas. From a total of 53 carcinomas, 23 showed positive and 30 a negative reaction to galectin-3. Thus, galectin-3's sensitivity to discriminate between benign and malignant lesions was 94% while its specificity was 43%. When comparing follicular carcinoma with adenoma, sensibility was 19% while specificity was 91%. The positive predictive value was 56% and the negative predictive value 66%. Galectin-3 was most useful for identifying papillary thyroid carcinoma.
Galectin-3 has limited value to distinguish benign from malignant thyroid lesions. The reaction must be considered positive when at least 25% of cells are marked.
半乳糖凝集素-3被认为有助于识别术语“滤泡性肿瘤”中包含的病变。
评估半乳糖凝集素-3区分不同甲状腺病变的能力，并确定一个表达设定点，在此点假阳性结果最少。
分析26例滤泡癌和104例各种甲状腺病变（8例桥本甲状腺炎、18例甲状腺肿、44例腺瘤、27例乳头状癌和7例正常腺体）。采用免疫组织化学方法检测半乳糖凝集素-3（NCL-GAL-3，1:100，英国诺沃卡斯尔公司）。以盲法评估表达强度、表达百分比及其通过2×2表格识别上述甲状腺实体的能力。确定最小反应设定点值，并选择假阳性病例最少的那个值。
当25%的细胞被标记时，反应被认为是阳性，在这种情况下，桥本甲状腺炎、甲状腺肿或残留组织对半乳糖凝集素-3均为阴性。在44例腺瘤中有4例、26例滤泡癌中有5例、27例乳头状癌中有18例检测到半乳糖凝集素-3阳性反应。在总共53例癌中，23例对半乳糖凝集素-3呈阳性反应，30例呈阴性反应。因此，半乳糖凝集素-3区分良性和恶性病变的敏感性为94%，特异性为43%。当比较滤泡癌与腺瘤时，敏感性为19%，特异性为91%。阳性预测值为56%，阴性预测值为66%。半乳糖凝集素-3对识别甲状腺乳头状癌最有用。
半乳糖凝集素-3在区分甲状腺良性和恶性病变方面价值有限。当至少25%的细胞被标记时，反应必须被认为是阳性。
Zotero 插件